Pharmaceutical manufacturing depends on repeatable inspection. A tablet with a crack, chip, stain, discoloration or other visible anomaly can signal a problem that deserves attention before product moves further downstream. Human inspection remains valuable, but it is inherently variable and difficult to scale consistently across long runs, multiple products and changing operators. Computer vision offers…
How on-site GMP training drives competitive advantage in pharmaceutical manufacturing
In pharmaceutical manufacturing, regulatory compliance isn’t optional. Good Manufacturing Practice (GMP) standards shape every stage of production, from raw material handling to final product release. Companies that treat on-site GMP training as a strategic investment rather than a compliance checkbox gain measurable advantages in efficiency, audit readiness and market competitiveness. Tailored programs can transform compliance…
ERWEKA Digital Dissolution Offline System automates sampling on DT 950 and DT 9510 platforms
ERWEKA is highlighting its Digital Dissolution Offline System for the DT 950 and DT 9510 series, an integrated offline sampling solution designed to automate dissolution workflows while maintaining pharmacopoeia compliance on existing DT platforms. The system pairs guided digital control with modular hardware to help QC labs reduce manual handling and improve consistency. The solution…
Confidently navigate the transition from bench to batch
Facility design challenges for small biopharma startups For small biopharma startups, the leap from groundbreaking discoveries in the lab to full-scale drug production is both exhilarating and daunting. While scientific innovation drives initial success, translating laboratory methods into manufacturing processes presents challenges beyond technical expertise. For all of the hurdles both compliance and technical rigor…
Navigating the new regulatory terrain pharma companies face with IRA and 340B
The ever-evolving landscape of pharmaceutical regulations has long been challenging to navigate, but now pharma companies face additional complexities with the introduction of the Inflation Reduction Act (IRA) and the ongoing implementation of the 340B drug pricing program. In recent years, the IRA has made waves for its impact on the pharmaceutical industry, including proposals…
No room for error: How a holistic quality management strategy can help pharma firms adhere to strict quality standards
Ever heard the phrase “one bad apple spoils the barrel”? The proverb rings especially true in pharmaceutical manufacturing, where even trace amounts of contaminants can have grave consequences for patient safety. “In the case of pharma, the stakes are so high that even the tiniest contaminants can endanger patients and result in wasted therapeutics, amounting…